More than 90 Penn State football players will compete on July 13 in an event where they plan to tackle kidney cancer. Well, maybe they won't literally tackle kidney cancer -- wouldn't that be nice -- but by raising awareness and funding, they'll surely make a difference.

The strength and conditioning event, called Lift For Life, will benefit the Kidney Cancer Association for the fifth year in a row. In past years, it's generated more than $148,000. In the 2005-06 year alone, $60,000 was raised for this rare disease.

Lift For Life challenges the mental and physical endurance of student-athletes and consists of 11 exercises. Think traditional bench and leg presses and the less conventional giant tire flip and iron cross and you've got an idea of what will take place in just one week.

Andy Thomas, of Watford, Hertfordshire, UK, who is a kidney cancer survivor, has created a new website called KidneyCancerResource.com. The site contains information on kidney cancer and other urological cancers . Thomas has created this site along with a fellow kidney/bladder cancer survivor, Greg.

KidneyCancerResource.com is a wiki site where multiple authors can collaborate on creating and maintaining content. Thomas intends on building a 'living, organic site' where patients, caregivers and medical professionals can contribute and share information.

Thomas was diagnosed with kidney cancer last year and underwent a successful radical nephrectomy. You can read his story, from a patient's perspective,here. Since then, Thomas' s prognosis is considered good. Thomas has returned to work and has also made a commitment to remaining as fit as possible.

Symptoms of kidney cancer include blood in the urine, pain in the side that does not go away, a lump or mass in the side or the abdomen and weight loss, tiredness or fever. These symptoms do not mean that cancer is definitely present, but anyone with such symptoms should see a doctor as soon as possible.

If you or someone you love has been diagnosed with kidney cancer and you are looking for more information, here is a compilation of sites from KidneyCancerResource, for both the UK and the US and around the world.

David Foster was diagnosed with Advanced Renal Cell Carcinoma in April 2005. Translation: stage four kidney cancer and the sixth deadliest form of cancer. Not a great disease to acquire. Also not the end of the world. Just ask David who is busy working as a National Strategic Advisor in Augusta, Georgia, headlining within the independent magazine community, hanging out with dog Gracie, and documenting his journey in a blog he calls David Foster's Kicking Kidney Cancer's Arse.

He's no wimp, this guy. Just read his June 23 post, titled May kill me, but it ain't gonna beat me. He didn't let that hard-nosed kid Jerry whip him when he was eight -- he smacked him so hard in the lunchroom, Jerry was left stumbling and bleeding -- and he won't let cancer bully him either. Still, David admits: he is sick. He explains it all in a post he calls Mr. Foster, are you really sick?

David got an e-mail one day. It read, Mr. Foster, are you really sick? I read your blog and you don't sound sick.

New cancer drug Torisol was approved on Wednesday by the FDA for use with renal cell carcinoma, an advanced form of kidney cancer.

Torisol, also known as temsirolimus, is an enzyme inhibitor made by Wyeth Pharmaceuticals and has shown promise for prolonging patient survival. It's the third kidney cancer drug approved in the past 18 months -- the other two are Nexavar, intended to delay disease progression, and Sutent, for tumor size reduction.

Many kidney cancer patients are cured by surgery. About 35 percent of patients, however, experience a recurrence or a spread of the disease. Until just recently, there were no effective drugs to control these issues. Now there are several -- and Torisol is the one showing modest improvement in survival for patients with the most advanced tumors. Further study will indicate whether or not the drug is useful for patients with less extensive metastatic disease.

Don't delay. There's no better time than the present to get your weight in check. Especiallly now that The American Cancer Society is reporting that maintaining a healthy weight is at the top of their cancer prevention list.

"We know that obesity is related to a number of different cancers, breast cancer among post-menopausal women, colon cancer, esophageal, kidney cancer," says Colleen Doyle of American Cancer Society spokeswoman.

This makes the ACS recommendations more urgent than ever.

The ACS urges individuals to eat a diet rich in fruits, vegetables, and whole grains and to exercise at least five days per week.

There are no guarantees, of course, that these practices will hold off cancer. But "the good news is that a lot of people think they don't have any control over their risk of cancer and we're here to tell people that absolutely you do have some control," says Doyle.

It is estimated that poor diet and lack of physical activity cause about one-third of cancer deaths each year, about the same number of cancer cases caused by smoking.

Toby Keith has been touched by childhood cancer. One of his original band mates lost his daughter Allison in August of 2003 to a form of kidney cancer called Wilm's tumor.

The country singer is sponsoring the fourth annual charity golf tournament that will once again benefit the families of children fighting cancer. The event will begin with an auction and party in downtown Oklahoma City on April 27, and continue with the golf tournament the following morning.

The proceeds will benefit Ally's house, which Keith helped establish in memory of his friend's daughter. The charity helps pay for medical bills, prescriptions, housing, transportation, toys, food, clothing and other expenses for families that have children with cancer.

Some of the items to be auctioned off are:

• Trip to see Keith in concert in Las Vegas
• Memorabilia from Garth Brooks, Sammy Hagar and Bob Seger
• Sports memorabilia autographed by Tiger Woods and baseball Hall of Famer Mickey Mantle

Toby Keith comments about Ally's House -- "This is a special charity to me. I saw firsthand how a child's cancer diagnosis can devastate a family. Please join me in supporting these kids through Ally's House."

Devastating blood born fungal infections that can be lethal for cancer, HIV/AIDS, and organ transplant patients may be treated more successfully, thanks to a new drug delivery method of Amphotericin B developed by researchers at the University of British Columbia in Vancouver. Because the oral form of the drug is easier to administer and cheaper than intravenous delivery more patients would have access to the medicine. Amphotericin B deoxycholate (AmBd) has been the gold standard for the treatment of systemic mycoses for the past 5 decades. The intravenous form of the drug caused severe kidney toxicity as well as serious tissue damage at the intravenous injection site. This research was triggered by clinicians needing a way to kill these fungal infections without risking the patient's kidney. The new form can be can be taken by mouth with minimal side effects boosting effectiveness and dramatically reducing toxicity.

It was effective in treating candida albicans an infection prevalent in HIV/AIDS and cancer patients receiving chemotherapy,and can cause symptoms ranging from cough to brain damage. Research funding for this project was provided by the Canadian Institutes of Health Research, Canada's major agency responsible for funding health research. Composed of 13 Institutes, CIHR provides leadership and support to more than 10,000 health researchers and trainees across Canada.

Doctors prescribing anemia drugs for patients with kidney disease and cancer were urged by the Food and Drug Administration (FDA) on Friday to carefully dispense of these drugs due to an increased risk of death and other serious problems, such as blood clots, strokes, and heart attacks in patients with chronic kidney failure and rapid tumor growth in patients with head and neck cancer who receive doses higher than recommended.

The potentially harmful drugs, sold under than brand names Procrit, Epogen, and Aranesp, are genetically engineered versions of a natural protein -- called erythropoietin -- that increases the number of red blood cells. The drugs, with combined 2006 U.S. sales of $10 billion, are commonly used for patients with certain forms of kidney disease and for those receiving chemotherapy for cancer.

The FDA is adding warnings to the drugs' labels that will strongly instruct doctors to use the lowest possible dose needed to help patients avoid blood transfusions.

The FDA will also take a close look at how the drugs are marketed, including claims the drugs can improve the quality of life.

A meeting of FDA officials to further discuss this issue, believed to stem from drug overuse by dialysis centers and oncologists who make more money by using more of the drugs. is scheduled for May 10. Recommendations could lead to additional revisions of the drugs' labels.

It's been one year since Dana Reeve, wife of the late Christopher Reeve, died of lung cancer at the age of 44. And the grace of this woman, who came to represent the non-smoking population of lung cancer victims, is being honored by the Lung Cancer Alliance.

"Lung Cancer Alliance extends its most heartfelt thoughts to the family
and friends of Dana Reeve," says Laurie Fenton, president of the alliance.

"Dana's beauty, grace and valiant struggle against lung cancer will remain indelibly etched in our hearts and minds. In her memory -- and in the memory of loved ones lost to this disease, smoker or not -- let us come together to replace decades of stigma and neglect with hope, greater compassion and support for those living with or at risk for this disease. It is the right thing to do."

The Lung Cancer Alliance is the only national non-profit organization dedicated to patient support and advocacy for those living with lung cancer, the number one cancer killer.

Lung cancer takes more lives -- about 160,000 Americans this year -- than breast, prostate, colon, liver, kidney cancers and melanoma combined.

Aspirin and painkillers such as ibuprofen have been deemed too risky for use in the prevention of colon cancer, according to a federal task force.

The risk of intestinal bleeding, stroke, kidney failure, and other health problems led the US Preventative Services Task Force to conclude that taking more than 300 milligrams per day of drugs like Motrin, Advil, and Aleve is just too risky to outweigh the potential benefits of preventing cancer. And while taking less than 100 milligrams of such drugs can reduce the risk of heart disease, it does nothing to lower the rate of colon cancer.

Details about this task force study are published in Monday's issue of the Annals of Internal Medicine.

It's already been established that type 2 diabetes increases the risk of pancreatic cancer. And now, research indicates there is also a link between type 1 diabetes and this type of cancer.

The risk is relatively small -- but still, those with type 1 diabetes have a likelihood of developing pancreatic cancer that is twice as high as in non-diabetics. This is similar to the risk those with type 2 diabetes face.

There are many theories about the link between diabetes and pancreatic cancer, and this research -- published in the British Journal of Cancer -- helps narrow the scope of the theories.

For example, one researcher says the study rules out "a cancer-inducing role of the insulin-producing beta-cells in the pancreas, because in type 1 diabetes these cells have largely or entirely been destroyed."

Experts say people with diabetes should focus their attention on the most common complications of diabetes such as heart disease, eye disease, and kidney disease and not on the very small risk of cancer. In the whole scheme of things, pancreatic cancer is a rare disease -- and even twice the risk is not very significant.

Cancer drug Nexavar has made its point. It can help people with liver cancer survive longer.

Bayer Pharmaceuticals and Onyx Pharmaceuticals announced Monday that advanced stage clinical trials for this drug will end early. And now patients in the placebo arm of the study can begin treatment with the actual drug.

It's been a long road for researchers who have been searching for a liver cancer treatment that can target tumors with minimal side effects while extending life for months or even years.

It is estimated that 16,780 people in the United States will die from liver cancer in 2007 -- and it seems Nexavar, a drug initially predicted to fail when used for liver cancer -- may help save some of these lives.

Bayer and Onyx are planning to pursue FDA approval for this drug that has already been approved for kidney cancer.

I once waited to see my oncologist -- in a room with nothing more than outdated magazines and my own wandering mind -- for four hours. I offered up 20 hours of my time for chemotherapy treatments and then spent five days -- two times, for a total of ten days -- waiting in the hospital for doctors to determine how to raise my blood counts and decrease my fever after the completion of a dose-dense chemotherapy attack. I traveled to and from radiation appointments for 35 days, spending an average of 90 minutes on each of these round-trip excursions. I reclined in an infusion chair every three weeks for 12 months so that a new breast cancer wonder drug could sail through my veins. I spent 52 hours in that chair. And I spent countless hours pouring out my emotions to a counselor, in an attempt to clear my mind of all that cancer took from me -- including my time.

These are just seven memories I have of time lost to cancer. There are others -- countless others -- but this should suffice as proof that among all the potential side effects that accompany cancer, loss of time is a guarantee.

According to the first study to put a price tag on the time patients spend battling cancer, it seems the disease steals at least $2.3 billion worth of time for patients in the first year of treatment alone.

Eleven of the most common cancers were included in the study. And it was determined that 368 hours are lost during the first year of treatment for ovarian cancer. For lung cancer, 272 hours are lost. For kidney cancer, 193 hours go down the drain. These hours don't take into account time spent in bed recovering from surgery or chemotherapy treatments. It accounts only for time engaged in actively receiving care -- it counts chemotherapy, radiation, blood tests, scans, surgery, check-ups, waiting to see doctors, and driving to and from appointments.

The study, published in the Journal of the National Cancer Institute, sheds new light on the burden of commitment -- the human cost of cancer.

"Cancer is more than the just the dollars and cents for the medicines and the treatments and the doctors. It's also the lost opportunities for the patients," said the American Cancer Society's Dr. Len Lichtenfeld, of this overlooked reality.

Lichtenfeld says this study demonstrates the need for early detection. The earlier cancer is caught, the less time patients spend in the system. It also shows the need for more targeted therapies that spare patients physical side effects and allow them opportunities for taking pills at home instead of receiving treatment in clinics.

I would love to have back the time I spent treating and recovering from cancer. But I'm not heartbroken over my lost time. Because it bought me something in the end -- more time.

Ohio State quarterbacks coach Joe Daniels is part of a coaching staff preparing to take on the University of Florida in the NCAA Football National Championship in Glendale, Arizona next week. It's a big game, with big stakes -- but it's just one match-up Daniels plans to tackle this year. He's also in the midst of a game with cancer -- a game he plans to win.

Daniels, a 64-year-old assistant to head coach Jim Tressel and contender for the Broyles Award, given January 16 to the nation's top assistant coach, was diagnosed with kidney cancer this past year shortly after suffering a heart attack and while mourning the death of his mother. Although it was a tough year, he still managed to make it through his 37th season as an assistant coach. He and his wife, Kathy, say it's been a hard road but a blessed one too.

"Cancer is a terrible disease," says Kathy. "But in a lot of ways, it's enriched our lives. It's not the burden a lot of people expect it to be. Maybe it's because we've been so fortunate to have football as a distraction."

The Buckeyes' 12-0 season -- complete with a Heisman Trophy victory for quarterback Troy Smith -- was quite a distraction for Daniels who was able to avoid chemotherapy and radiation and is faithfully taking a drug called Sutent to treat his malignant tumor. He takes a pill for 28 days, then takes 14 days off, and then begins again.

Medically, everything seems to be working out just fine for Daniels. His monthly check-ups continue to deliver good news, and he reports he has felt good, with just a bit of fatigue, for the entire season.

Now about that other game. Tune into the FOX network on Monday, January 8 at 8:15 PM -- and watch it all unfold.

At the end of November, EarthLink CEO Garry Betty took a medical leave of absence from his job to fight adrenocortical cancer, a serious form of cancer characterized by a tumor that occurs in the adrenal glands above the kidneys. On Tuesday, Betty died at his Atlanta home from complications of the disease. He was 49.

Betty joined the internet service provider EarthLink in 1996 and helped the regional company grow from a provider with 500,000 subscribers into a national powerhouse with more than five million subscribers.

"Garry was instrumental in building EarthLink into the company it is today," EarthLink Chairman Robert M. Kavner said in a recent statement.

EarthLink was just one of Betty's successful ventures. He began his career at IBM Corp. and won the IBM President's Excellence Award in 1982 for his work on the company's personal computer. He also served as CEO of Digital Communications Associates Inc. and at the time became the youngest CEO of a company listed on the New York Stock Exchange.

Betty, who graduated from the Georgia Institute of Technology in 1979 with a degree in chemical engineering, was responsible for 2,200 EarthLink employees. And in support of his team, he attended the company's 2006 Christmas party just three weeks after receiving his diagnosis.

"He put on a tux and came out for a night to make all of us feel better," said Mike Lunsford, interim EarthLink CEO. "And he succeeded."

Betty is survived by his wife, Kathy.